MA DM DSc MRCP(UK) FRCR
Friends of ANCHOR Clinical Chair in Oncology
- About
-
- Email Address
- anne.kiltie@abdn.ac.uk
- Office Address
Room 5.053
- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
I qualified in medicine from the Universities of Cambridge and Oxford and trained in Clinical Oncology at the Christie Hospital, Manchester, and Cookridge Hospital, Leeds. I undertook my DM at the Paterson Institute, University of Manchester and was a Clinical Research Fellow at ICRF Clare Hall before taking up a Senior Lecturer/Honorary Consultant Clinical Oncologist appointment at the University of Leeds in 2001. I moved to the Department of Oncology, University of Oxford in 2009, and obtained my DSc and personal chair in 2016.
I took up my appointment as Friends of ANCHOR Clinical Chair of Oncology at the University of Aberdeen in June 2021.
My research focusses on exploiting dietary fibre manipulation and its effects on the gut microbiome as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Qualifications
- DSc Medical Sciences2016 - University of Oxford
- DM Medical Sciences1999 - University of Oxford
- BM BCh Medicine1988 - University of Oxford
- BA Medical Sciences1985 - University of Cambridge
- MRCP(UK) General Medicine1992 - Royal College of Physicians of England
- FRCR Clinical Oncology1995 - Royal College of Radiologists
- MA Medicine1989 - University of Cambridge
- MA Medicine1999 - University of Oxford
Memberships and Affiliations
- Internal Memberships
-
Jul 2021 - present Member of the Rowett Institute Ethics Panel
Oct 2021 - present Member of Friends of ANCHOR Research Advisory Group
Oct 2024 - present Elected member Senatus Academicus
Oct 2024 - present Member of Honorary Degrees Committee
- External Memberships
-
Apr 2024 - present Chair, Scottish Radiation Research Forum (ScoRRF)
Jun 2023 - present Member of RAIDER TrialTranslational Working Group
Jan 2022 - present Member of Scientific Review Group BCAN Bladder Cancer Research Innovation Award 2022
Jan 2022 - present Member of Scottish Radiotherapy Research Forum Committee
Oct 2018 - present Bladder Cancer Advocacy Network (BCAN) Bladder Cancer Research Network Management Committee
Dec 2017 - present Member of Editorial Board of European Urology Oncology
Oct 2016 - present Associate Editor of Bladder Cancer
2014 - present Grant reviewer for Italian Association for Cancer Research (AIRC)
Sept 2012 - present British Uro-oncology Group Executive Committee Trustee
Jan 2012 - present Royal College of Radiologists representative on Advisory Appointments Committees
Latest Publications
Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity
Microbiome, vol. 12, no. 1, 89Contributions to Journals: ArticlesHow do tumours outside the gastrointestinal tract respond to dietary fibre supplementation?
BMJ Oncology, vol. 2, no. 1, e000107Contributions to Journals: Review articlesField-cycling imaging in ovarian cancer: a novel technology
International Journal of Gynecological Cancer, vol. 33, no. 8, pp. 1329-1330Contributions to Journals: Comments and DebatesGenome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights
European Urology, vol. 84, no. 1, pp. 127-137Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1016/j.eururo.2023.04.020
- [ONLINE] View publication in Scopus
Exploiting dietary fibre and the gut microbiota in pelvic radiotherapy patients
British Journal of Cancer, vol. 127, pp. 2087–2098Contributions to Journals: Review articles
Prizes and Awards
Development Trust Award for Philanthropy and Alumni Engagement, The Principal’s Prizes for Research and Engagement, University of Aberdeen Excellence Awards, Apr 2024
- Research
-
Research Overview
Tumours in the pelvis, including bladder, prostate and colorectal cancer and gynaecological cancers may be treated by surgical removal or organ-preserving radiotherapy-based treatments. Current organ-preservation standard of care for most tumour sites includes addition of radiosensitising chemotherapy to improve tumour control. However, this often comes at the expense of increased radiotherapy-induced side effects to the surrounding normal tissues, including the intestines. Furthermore, such combined treatments are often not tolerated by elderly patients. With the proportion of over 75-year olds set to double by 2050, there is an urgent need to find alternative approaches to radiosensitisation.
Having worked on histone deacetylase inhibitors, which we showed to be effective tumour radiosensitisers without additional acute and late small intestinal toxicity in in vivo models, we are now working to exploit dietary fibre manipulation and the gut microbiota as an ‘endogenous’ means of radiosensitising tumours without increasing radiation toxicity to the surrounding normal tissues including the intestines.
Research Areas
Applied Health Sciences
Biomedical Sciences
Nutrition and Health
Research Specialisms
- Medicine
- Food Science
- Bacteriology
- Oncology
Our research specialisms are based on the Higher Education Classification of Subjects (HECoS) which is HESA open data, published under the Creative Commons Attribution 4.0 International licence.
Supervision
Supervisees
- MS POLLY NOCK
- MISS ANAM WAJID
- DR NANAK BHAGAT
- MS MEREL VAN DEN HAAK
- MR ADAM POTTER
Funding and Grants
- Exploiting human microbiota-associated in vivo models for mechanistic studies to understand the benefits of dietary fibre supplementation in patients with prostate cancer. NHS Grampian Charity (£92,422.14) Kiltie AE, 15 Nov 2024 – 31 Oct 2025.
- The role of intestinal dendritic cells in mediating tumour and normal tissue responses to dietary fibre manipulation. Friends of ANCHOR Pilot Research Funding (£14,345) AE Kiltie, co-applicants: A Moomin, H Wilson, J Coombes, 1 Aug 2024-31 Jul 2025. RG17583.
- Role of intestinal macrophages in the protective effects of dietary fibre supplementation during radiotherapy. Medical Research Scotland PhD Studentship (£126,565.82) AE Kiltie, co-applicants: H Wilson, J Coombes, 1 Oct 2024 – 30 Sept 2028. RG17405.
- In gut health not all dietary fibres are equal: diet meets artificial intelligence. RESAS PhD studentship (Anam Wajid; £133,446), J Kyle, AE Kiltie (joint lead supervisors), K Scott, A Ayesh, 1 Jan 2024 to 31 Mar 2027.
- Dietary fibre supplementation to delay disease progression in early prostate cancer: preparatory work to develop a feasibility study (DEFINITE study) Friends of ANCHOR (£22,000) AE Kiltie, co-applicants: J Royle, J Kyle, S MacLennan, 1 Oct 2023 – 31 Dec 2024. RG17168.
- Feasibility of using National Bowel Screening Programme surplus qFIT samples to investigate the gut microbiota FUTURISTIC study). NHS Grampian Charity (£11,269.44), AE Kiltie, co-applicants: F Din, S McSorley, 1 Oct 2023 – 31 Mar 2025. GCA23249.
- Exploiting the gut microbiota and its metabolites in pelvic cancer to improve patient outcomes (PELICAN-23). NHS Grampian Endowment Fund (£130,505.37 plus £30,897.41 = £161,402.78) AE Kiltie, G Ramsay (Co-PI), co-applicants: J Royle, K Dimitropoulos, J Grant, G Horgan, G MacDonald, R McMenimen, M Gurumurthy, L Samuel, 1 Sept 2022 – 30 Sept 2025. ES900/EA4021.
- A human volunteer study of the effects of psyllium and inulin on the gut microbiome and metabolites: can we identify responders and non-responders to optimise outcomes for pelvic radiotherapy patients (PIGMent study)? Friends of ANCHOR /University of Aberdeen Development Trust PhD studentship (£168,500) AE Kiltie, co-applicants: A Johnstone, K Scott, A Walker, G Horgan, 1 Oct 2022 – 30 Sept 2026.
Datasets
-
Data from: Dietary fibre supplementation enhances radiotherapy tumour control and alleviates intestinal radiation toxicity
Abstract Background Non-toxic approaches to enhance radiotherapy outcomes are beneficial, particularly in ageing populations. Based on preclinical findings showing that high-fibre diets sensitised bladder tumours to irradiation by modifying the gut microbiota, along with clinical evidence of prebiotics enhancing anti-cancer immunity, we hypothesised that dietary fibre and its gut microbiota modification can radiosensitise tumours via secretion of metabolites and/or immunomodulation. We investigated the efficacy of high-fibre diets combined with irradiation in immunoproficient C57BL/6 mice bearing bladder cancer flank allografts. Result Psyllium plus inulin significantly decreased tumour size and delayed tumour growth following irradiation compared to 0.2% cellulose and raised intratumoural CD8+ cells. Post-irradiation, tumour control positively correlated with Lachnospiraceae family abundance. Psyllium plus resistant starch radiosensitised the tumours, positively correlating with Bacteroides genus abundance and increased caecal isoferulic acid levels, associated with a favourable response in terms of tumour control. Psyllium plus inulin mitigated the acute radiation injury caused by 14 Gy. Psyllium plus inulin increased caecal acetate, butyrate and propionate levels, and psyllium alone and psyllium plus resistant starch increased acetate levels. Human gut microbiota profiles at the phylum level were generally more like mouse 0.2% cellulose profiles than high fibre profiles. Conclusion These supplements may be useful in combination with radiotherapy in patients with pelvic malignancy. Video Abstract- DOI
- 10.6084/m9.figshare.c.7234207.v1
- Publisher
- Figshare
- Links
- Date Made Available
- 29 December 2024
- Related Research Outputs
- Contributors
- Then, C. K. (Creator), Paillas, S. (Creator), Moomin, A. (Creator), Misheva, M. D. (Creator), Moir, R. A. (Creator), Hay, S. M. (Creator), Bremner, D. (Creator), Roberts (nee Nellany), K. S. (Creator), Smith, E. E. (Creator), Heidari, Z. (Creator), Sescu, D. (Creator), Wang, X. (Creator), Suárez-Bonnet, A. (Creator), Hay, N. (Creator), Murdoch, S. L. (Creator), Saito, R. (Creator), Collie-Duguid, E. S. R. (Creator), Richardson, S. (Creator), Priestnall, S. L. (Creator), Wilson, J. M. (Creator), Gurumurthy, M. (Creator), Royle, J. S. (Creator), Samuel, L. M. (Creator), Ramsay, G. (Creator), Vallis, K. A. (Creator), Foster, K. R. (Creator), McCullagh, J. S. O. (Creator), Kiltie, A. E. (Creator)
- Teaching
-
Teaching Responsibilities
ME3013 MBChB SSC2: supervisor
BM4501 BSc Honours project: supervisor
RN5504 Nutrition and Health through the Life Stages: lecture
RN5505 Clinical Nutrition: lecture and seminar
RN5503 Clinical Nutrition for Disease Prevention: lecture
Non-course Teaching Responsibilities
I am a Regent for the MB ChB Regent Scheme.
- Publications
-
Page 7 of 10 Results 61 to 70 of 96
Polymorphisms in DNA repair genes, smoking, and bladder cancer risk: Findings from the International Consortium of Bladder Cancer
Cancer Research, vol. 69, no. 17, pp. 6857-6864Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1158/0008-5472.CAN-09-1091
- [ONLINE] View publication in Scopus
Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer
Nature Genetics, vol. 41, no. 9, pp. 991-995Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/ng.421
- [ONLINE] View publication in Scopus
Papillary and muscle invasive bladder tumors with distinct genomic stability profiles have different DNA repair fidelity and KU DNA-binding activities
Genes Chromosomes and Cancer, vol. 48, no. 4, pp. 310-321Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1002/gcc.20641
- [ONLINE] View publication in Scopus
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types
Nature Genetics, vol. 41, no. 2, pp. 221-227Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/ng.296
- [ONLINE] View publication in Scopus
Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity
Molecular Cancer Therapeutics, vol. 8, no. 1, pp. 203-213Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1158/1535-7163.MCT-08-0959
- [ONLINE] View publication in Scopus
Cancer biomarkers associated with damage response genes
The DNA Damage Response: Implications on Cancer Formation and Treatment. Springer Netherlands, pp. 307-330, 24 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1007/978-90-481-2561-6_14
- [ONLINE] View publication in Scopus
Molecular epidemiology of DNA repair genes in bladder cancer
Cancer Epidemiology: Volume II: Modifiable Factors. Verma, M. (ed.), pp. 281-306, 26 pagesChapters in Books, Reports and Conference Proceedings: Chapters- [ONLINE] DOI: https://doi.org/10.1007/978-1-60327-492-0_12
- [ONLINE] View publication in Scopus
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer
Nature Genetics, vol. 40, no. 11, pp. 1307-1312Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1038/ng.229
- [ONLINE] View publication in Scopus
In Reply to Dr. Rosario et al.
International Journal of Radiation Oncology Biology Physics, vol. 71, no. 5, pp. 1602Contributions to Journals: Letters- [ONLINE] DOI: https://doi.org/10.1016/j.ijrobp.2008.03.038
- [ONLINE] View publication in Scopus
Analysis of variants in DNA damage signalling genes in bladder cancer
BMC Medical Genetics, vol. 9, 69Contributions to Journals: Articles- [ONLINE] DOI: https://doi.org/10.1186/1471-2350-9-69
- [ONLINE] View publication in Scopus